From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target

0:00-9:43

Founder & CEO Clarissa Desjardins describes Congruence's Revenir product engine and walks us through programs that include MC4R deficient obesity, which is in the clinic, alpha-1 antitrypsin deficienty, and Parkinson's.

B-

BiotechTV - News

@biotechtvnews

#congruencetherapeuticsuses #developnovelsmall #highprofilegenetic #lifesciences

The Nile